These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6104912)

  • 1. Ergot and catecholamine potencies at catecholamine receptors.
    Titeler M; Seeman P
    Adv Biochem Psychopharmacol; 1980; 23():35-40. PubMed ID: 6104912
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple CNS receptor interactions of ergot alkaloids: affinity and intrinsic activity analysis in in vitro binding systems.
    U'Prichard DC
    Adv Biochem Psychopharmacol; 1980; 23():103-15. PubMed ID: 6249089
    [No Abstract]   [Full Text] [Related]  

  • 3. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors.
    Sibley DR; Creese I
    Mol Pharmacol; 1983 May; 23(3):585-93. PubMed ID: 6223205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The affinities of ergot compounds for dopamine agonist and dopamine antagonist receptor sites.
    Goldstein M; Lew JY; Sauter A; Lieberman A
    Adv Biochem Psychopharmacol; 1980; 23():75-82. PubMed ID: 7395625
    [No Abstract]   [Full Text] [Related]  

  • 5. On the antagonism of ergot alkaloids and dopamine by phenothiazines.
    Stone TW
    Experientia; 1974 Jul; 30(7):827-9. PubMed ID: 4847689
    [No Abstract]   [Full Text] [Related]  

  • 6. Central monoamine synapses as sites of action for ergot drugs.
    Fuxe K; Ogren SO; Agnati LF; Andersson K; Hall H; Köhler C; Fredholm B
    Adv Biochem Psychopharmacol; 1980; 23():41-62. PubMed ID: 6104914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of ergot compounds with dopamine receptors and endocrine functions.
    Flückiger E
    J Neural Transm Suppl; 1983; 18():189-204. PubMed ID: 6576114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Labelling of high (D-2 receptor) and low affinity sites by [3H]domperidone in homogenates of the corpus striatum of the rat.
    Rzezniczak HW; Gundlach AL; Beart PM
    Neurosci Lett; 1982 May; 30(1):63-8. PubMed ID: 6124917
    [No Abstract]   [Full Text] [Related]  

  • 9. Adaptive changes of the striatal dopamine system induced by repeated administration of neuroleptics and ergot derivatives.
    Bürki HR
    Adv Biochem Psychopharmacol; 1980; 24():65-8. PubMed ID: 6105806
    [No Abstract]   [Full Text] [Related]  

  • 10. [Profile of the adverse effects of neuroleptic drugs in relation to its receptor binding].
    Gerlach J
    Nord Med; 1987; 102(4):120-3. PubMed ID: 2884620
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects.
    Richelson E
    J Clin Psychiatry; 1984 Aug; 45(8):331-6. PubMed ID: 6146602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergic receptors.
    Bylund DB
    J Pharmacol Exp Ther; 1981 Apr; 217(1):81-6. PubMed ID: 6110776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural modifications of the ergopeptine molecule and their differential influence on the affinities to different receptor binding sites--a structure affinity analysis.
    Closse A; Bolliger G; Dravid A; Frick W; Hauser D; Pfäffli P; Sauter A; Tobler HJ
    Adv Biochem Psychopharmacol; 1983; 36():269-79. PubMed ID: 6305153
    [No Abstract]   [Full Text] [Related]  

  • 14. Interaction of catecholamine-derived alkaloids with central neurotransmitter receptors.
    Nimit Y; Schulze I; Cashaw JL; Ruchirawat S; Davis VE
    J Neurosci Res; 1983; 10(2):175-89. PubMed ID: 6313954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
    Oda T; Kume T; Izumi Y; Takada-Takatori Y; Niidome T; Akaike A
    Eur J Pharmacol; 2008 Nov; 598(1-3):27-31. PubMed ID: 18835264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuroleptics in geriatrics. Pharmacological criteria for a responsible choice and a correct use].
    van Wielink PS
    Tijdschr Gerontol Geriatr; 1984 Apr; 15(2):73-80. PubMed ID: 6144201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCCP enhances catecholamine release from the perfused rat adrenal medulla.
    Lim DY; Park HG; Miwa S
    Auton Neurosci; 2006 Jul; 128(1-2):37-47. PubMed ID: 16461015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similarities and dissimilarities between dopamine and neuroleptic receptors: further evidence for type 1 and type 2 dopamine receptors in the CNS.
    Spano PF; Memo M; Govoni S; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 24():113-21. PubMed ID: 6105769
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of ergot alkaloids on 3H-flunitrazepam binding to mouse brain GABAA receptors.
    Tvrdeić A; Pericić D
    Coll Antropol; 2003; 27 Suppl 1():175-82. PubMed ID: 12955907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A biochemical and neurophysiological comparison of opioids and antipsychotics.
    Clouet DH
    Ann N Y Acad Sci; 1982; 398():130-9. PubMed ID: 6130733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.